1mo
76% adjusted gross margin
Adjusted gross margin held at 76% while R&D increased 12% operationally
Management reported adjusted gross margin of 76% in Q2 alongside adjusted R&D expenses up 12% operationally due to increased spending in oncology and obesity candidates.
Read the full earnings transcript for PFE Q2 2026, or visit the Pfizer Inc. company page.
Explore more insights on the Highlights Feed.
1mo
Transaction execution momentum across Seagen, Metsera, and Biohaven
1mo
Financial Performance Summary
1mo
We feel extremely confident that we will -- even the most stretched scenarios that we are running, we will be able to maintain our dividend.
Albert Bourla
CEO, Pfizer Inc.
Context
In response to a Q&A asking what would have to transpire for the Board to consider cutting Pfizer’s dividend. Albert responded directly to a question about the conditions that could lead the Board to cut the dividend. He emphasized confidence even in “the most stretched scenarios” being modeled. He further reinforced that dividend growth should restart after the LOE period.
Dafinchi